Hypoaldosteronism secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Akshun Kalia (talk | contribs) |
No edit summary |
||
| Line 22: | Line 22: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Disease]] | |||
[[Category:Endocrinology]] | |||
[[Category:Nephrology]] | |||
[[Category:Emergency medicine]] | |||
[[Category:Medicine]] | |||
[[Category:Up-To-Date]] | |||
Latest revision as of 16:43, 18 October 2017
|
Hypoaldosteronism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hypoaldosteronism secondary prevention On the Web |
|
American Roentgen Ray Society Images of Hypoaldosteronism secondary prevention |
|
Risk calculators and risk factors for Hypoaldosteronism secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]
Overview
Effective measures for the secondary prevention of hypoaldosteronism include liberal salt intake of 4gm/day (to increase plasma sodium concentration), decreasing potassium intake and avoidance of drugs that affects renin angiotensin aldosterone system (RAAS) such as ACE inhibitors, ARBs, potassium sparing diuretics and β-Adrenergic receptor blockers.
Secondary Prevention
- Effective measures for the secondary prevention of hypoaldosteronism include:[1][2][3]
- Low potassium intake
- Salt intake of 4gm/day
- Avoid drugs affecting the renin angiotensin aldosterone system (RAAS) such as:
References
- ↑ Ben Salem C, Badreddine A, Fathallah N, Slim R, Hmouda H (2014). "Drug-induced hyperkalemia". Drug Saf. 37 (9): 677–92. doi:10.1007/s40264-014-0196-1. PMID 25047526.
- ↑ Kuijvenhoven MA, Haak EA, Gombert-Handoko KB, Crul M (2013). "Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia". Int J Clin Pharm. 35 (6): 1099–104. doi:10.1007/s11096-013-9830-8. PMID 23974985.
- ↑ Indermitte J, Burkolter S, Drewe J, Krähenbühl S, Hersberger KE (2007). "Risk factors associated with a high velocity of the development of hyperkalaemia in hospitalised patients". Drug Saf. 30 (1): 71–80. PMID 17194172.